Recordati
France - Saint-VictorBiotechnology
Focus: Recordati is a mid-cap specialty pharmaceutical company headquartered in France with 1,001–5,000 employees, focused on small-molecule manufacturing across oncology, rare diseases, endocrinology, cardiovascular, and hematology. The company is public and generates 67% of revenue from its flagship product ISTURISA.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
0
About Recordati
AI assessmentNot HiringNo open roles listed right now. Follow Recordati to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Recordati's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Late-stage
5 Phase 3+
LOE Risk
3 imminent
CARBAGLU
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$35M Part DStable
Peak9.1yr
Blockbuster-scale rare-disease drug; 11β-hydroxylase inhibitor generating 67% of company revenue with 9-year patent runway.
Help build intelligence for Recordati
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.